Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial

Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial

Abstract Introduction There have been no prior trials directly comparing the efficacy of different calcitonin gene-related peptide (CGRP) antagonists for migraine prevention. Reported are the results from the first head-to-head study of two CGRP antagonists, galcanezumab (monoclonal antibody) versus...

Full description

Bibliographic Details
Main Authors: Todd J. Schwedt, Tina M. Myers Oakes, James M. Martinez, Bert B. Vargas, Hitendra Pandey, Eric M. Pearlman, Diane R. Richardson, Oralee J. Varnado, Michael Cobas Meyer, Peter J. Goadsby
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-11-01
Series:Neurology and Therapy
Subjects:
Calcitonin gene-related peptide (CGRP)
CGRP antagonist
Galcanezumab
Gepant
Head-to-head
Migraine
Online Access:https://doi.org/10.1007/s40120-023-00562-w

Internet

https://doi.org/10.1007/s40120-023-00562-w

Similar Items